A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
Status:
Recruiting
Trial end date:
2026-03-27
Target enrollment:
Participant gender:
Summary
9 participants are expected to be enrolled for this open，single-armed clinical trial to
evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients
with relapsed/refractory head and neck cancer.